No Data
Express News | Sichuan Biokin Pharmaceutical Says Funds Will Be Used for Drug Research and Development
Express News | Sichuan Biokin Pharmaceutical Says It Plans to Raise up to 3.9 Bln Yuan via a-Share Private Placement
Baillie Gifford (688506.SH): plans to raise no more than 3.9 billion yuan through a private placement.
GLONGHUI reported on March 9 that Baili Tianheng (688506.SH) announced a plan to issue A shares to specific targets for the year 2025. The total amount of funds raised from this issuance will not exceed 3.9 billion yuan (including the principal), and after deducting issuance expenses, it will be used for Innovative Drugs research and development projects.
Sichuan Biokin Pharmaceutical Enrolls First Patient for Lung Cancer Trial; Shares Down 4%
Bailitihanheng (688506.SH): The innovative biological drug injection BL-B01D1 has completed the enrollment of the first subject in the phase III clinical trial.
Baile Tianheng (688506.SH) announced that the company's independently developed innovative biological drug, injectable BL-B01...
Baili Tianheng (688506.SH): The Phase III clinical trial for BL-B01D1 (an EGFR×HER3 dual antibody ADC) in combination with Osimertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer has completed its first subject en
On March 2, Gelonghui reported that Baillie Tianheng (688506.SH) announced that the Phase III clinical trial of its independently developed innovative biological drug, BL-B01D1 (EGFR×HER3 dual-targeting ADC), in combination with Osimertinib for first-line EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer, has recently completed the enrollment of the first subject. BL-B01D1 is a global exclusive dual-targeting ADC drug developed by the company that is currently in Phase III registration clinical trials, which can target both EGFR and HER3 simultaneously. Recently, BL-B01D1 combined with Osimertinib has been used for first-line.
